← Leaderboards
Christopher Nelson
Duke University
$1,555,537
Attributed
$1,555,537
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $367.1K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,555,537 · 3
By mechanism
R00$735,633 · 1
R35$733,790 · 1
K99$86,114 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Alexander M Kulminski$13,747,868
- Tatiana Segura$14,175,920
- Anatoliy I Yashin$18,815,780
- Karl-Dimiter Bissig$5,231,801
- Stephan Zuchner$30,061,220
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsAnimalsImmune ResponseVectorGenome EditingGenesGene TherapyGenomicsMediatingVector GenomeLongevityLiverGenetic TranscriptionDesignBrainDna DeliveryBlood ProductBlood Coagulation FactorAlpha 1-Antitrypsin DeficiencyDrug DevelopmentBlood CoagulationCrispr/Cas TechnologyCoagulation ProcessClinical Treatment
Grant awards (6)
Exploring genomic and cellular determinants of gene therapy durability$366,731
R35 · FY2025 · GM · contact PI
Exploring genomic and cellular determinants of gene therapy durability$367,059
R35 · FY2024 · GM · contact PI
Non-viral delivery of CRISPR/Cas9 for targeted gene replacement$241,722
R00 · FY2021 · EB · contact PI
Non-viral delivery of CRISPR/Cas9 for targeted gene replacement$245,989
R00 · FY2020 · EB · contact PI
Non-viral delivery of CRISPR/Cas9 for targeted gene replacement$247,922
R00 · FY2019 · EB · contact PI
Non-viral delivery of CRISPR/Cas9 for targeted gene replacement$86,114
K99 · FY2018 · EB · contact PI